CHARGED ALPHA
Stock Analysis
AZZ Unclassified Latest YouTube: Q1 FY2027

AZZ

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

AZZ Stock: The Boring Industrial That Beat, Raised Guidance, and Jumped 7%

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 FY2027
Podcast available
Yes
Current price
$147.21
-6.56 (-4.27%)
Trailing / Forward P/E
22.44x
Forward: 18.90x
Market cap / Volume
Volume:
Revenue / Earnings Growth
6.3%
Earnings: -69.6%
Margins
17.2% op
Gross: 23.8% · Net: 11.8%
Balance sheet
1.92x current
Debt / Equity: 39.5
52-week range / Beta
$92.98 - $162.20
Beta: 1.10
Analyst target
$164.00
Upside: 11.4%
Cash / shareholder return
2.37% FCF yield
Dividend yield: 0.53%

Company context

Industry: Specialty Business Services
Country: United States
Employees:
Price to book: 3.21x
Return on equity: 15.3%
AZZ Inc. provides hot-dip galvanizing and coil coating solutions in North America. It operates through the AZZ Metal Coatings; and the AZZ Precoat Metals segments. The company offers metal coating solutions for corrosion protection, including hot-dip galvanizing, spin galvanizing, powder coating, anodizing, and plating to the steel fabrication and other industries. It also provides aesthetic and corrosion protective coatings and related value-added services for steel and aluminum coil primarily serving the construction; appliance; heating, ventilation, and air conditioning; container; transportation; and other end markets. AZZ Inc. was incorporated in 1956 and is headquartered in Fort Worth, Texas.

Price chart

Market context for AZZ

Competitive view

AZZ vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

AZZ latest YouTube video thumbnail YouTube
AZZ
AZZ
Latest video
Q1 FY2027
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Abbott Laboratories latest YouTube video thumbnail YouTube
Abbott Laboratories
ABT
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
AZZ
$4.42B
AZZ
ADBE
$94.31B
ADBE
ABT
$175.37B
Abbott Laboratories
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
AZZ
22.4x
AZZ
ADBE
13.6x
ADBE
ABT
28.2x
Abbott Laboratories
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
AZZ
18.9x
AZZ
ADBE
8.6x
ADBE
ABT
16.6x
Abbott Laboratories
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
AZZ
6.3%
AZZ
ADBE
12.7%
ADBE
ABT
7.8%
Abbott Laboratories
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
AZZ
-69.6%
AZZ
ADBE
7.9%
ADBE
ABT
-19.7%
Abbott Laboratories
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
AZZ
17.2%
AZZ
ADBE
35.3%
ADBE
ABT
13.5%
Abbott Laboratories
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
AZZ
23.8%
AZZ
ADBE
89.4%
ADBE
ABT
56.5%
Abbott Laboratories
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
AZZ
11.8%
AZZ
ADBE
28.7%
ADBE
ABT
13.9%
Abbott Laboratories
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
AZZ
15.3%
AZZ
ADBE
63.0%
ADBE
ABT
12.3%
Abbott Laboratories
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
AZZ
2.4%
AZZ
ADBE
9.8%
ADBE
ABT
3.6%
Abbott Laboratories
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
AZZ
39.45x
AZZ
ADBE
61.44x
ADBE
ABT
64.77x
Abbott Laboratories
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
AZZ
1.92x
AZZ
ADBE
0.75x
ADBE
ABT
1.39x
Abbott Laboratories
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
AZZ
1.10
AZZ
ADBE
1.43
ADBE
ABT
0.61
Abbott Laboratories
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
AZZ
0.5%
AZZ
ADBE
ADBE
ABT
2.8%
Abbott Laboratories
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
AZZ
11.4%
AZZ
ADBE
14.8%
ADBE
ABT
15.8%
Abbott Laboratories

Related research

Non-quarter videos featuring AZZ

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-08

AZZ: The boring industrial that beat, raised guidance, and jumped 7% #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for AZZ

Each row is one earnings episode with every verified platform link available.

Q1 FY2027
Episode live
Published youtube podcast complete
AZZ Stock: The Boring Industrial That Beat, Raised Guidance, and Jumped 7%
Quarterly earnings-analysis entry for AZZ. Use the links on the right to open the video or podcast episode.